PharmEng International Inc.
TSX VENTURE : PII

PharmEng International Inc.

August 19, 2005 09:00 ET

PharmEng Adds to Senior Management Team

TORONTO, ONTARIO--(CCNMatthews - Aug. 19, 2005) - PharmEng International Inc. (TSX VENTURE:PII), a full-service consulting and contract manufacturing company, today announced the appointments of Ken Vice, Senior Director, Management Consultant Division; Jerry Holatko, Senior Director, Management Consultant Division; Zahir Popat, Vice President, Business Development and Charles Ivey, Senior Director, Corporate Development.

Ken Vice - Senior Director, Management Consultant Division - joined PharmEng on May 23, 2005 and is involved with the design, construction, equipment selection and start-up of the Keata Pharma facility in Cape Breton, Nova Scotia. He will also support operations at the Keata Pharma facility in Perth, Ontario. Mr. Vice has over thirty years in technical and engineering project management in the pharmaceutical, nutritional and food industries including the planning, design, and construction of manufacturing facilities.

Jerry Holatko - Senior Director, Management Consultant Division - joined PharmEng on July 18, 2005 and has responsibility to develop, promote and expand PharmEng in the medical devices sector in the areas of manufacturing, distribution and usage. Prior to joining PharmEng, Mr. Holatko was the Former Regional Manager, Medical Devices/BTOX Unit, Health Products and Food Branch Inspectorate for Health Canada. Within Health Canada, Mr. Holatko was responsible for the inspection of medical device firms, compliance verification of medical device incidents and related compliance and enforcement activities in addition to the inspection and compliance verification of issues dealing with blood, tissues, organs, and xenographs.

Zahir Popat - Vice President, Business Development - joined PharmEng on April 1, 2005. Mr. Popat's will be responsible for establishing global partnerships and alliances. Mr. Popat brings 25 years of knowledge and experience in the area of international pharmaceuticals, biotechnology and nutraceuticals. Mr. Popat has been instrumental in setting up distribution of generic pharmaceuticals in the Middle East, South East Asia and Africa with extensive experience in new product development, contract manufacturing, clinical trials and drug registration. Mr. Popat has been involved in direct negotiations with various Health Ministries worldwide and brings valuable specific pharmaceutical expertise with strong international relationships for sourcing of active pharmaceutical ingredients, drug master files, formulation dossiers and bioavailability of out-sourcing.

Charles Ivey - Senior Director, Corporate Development - joined PharmEng on July 25, 2005 and will be responsible for the overall direction of the company's investor relations program and will be active in corporate development inclusive of expanding the PharmEng Pharmaceutical Certificate Program. Prior to joining PharmEng, Mr. Ivey was Chairman and Lead Director of Centrinity Inc., a TSX listed company involved in the development and distribution of collaborative software. Mr. Ivey has extensive experience in early stage corporate strategic development with a focus on operations and financing activities having been responsible for start up projects in Canada, U.S., and the Caribbean. Mr. Ivey serves on a number of Boards and is active in numerous charitable organizations.

"These individuals, each in their own right, would be an asset with any company but for PharmEng to be able to attract and bring all four onto the team is indicative of our strong business plan and growth," said Alan Kwong, CEO and Managing Director. "The caliber of these individuals builds on the foundation that supports our core consulting and contract manufacturing business in North America and internationally," concludes Mr. Kwong.

About PharmEng International Inc.

PharmEng International Inc., headquartered in Toronto, Canada, is a full-service consulting and contract manufacturing company that serves the pharmaceutical and biotechnology industries in North America and internationally. Consulting services include project management, engineering, GMP, validation, calibration, regulatory compliance and certified training. Contract manufacturing includes pharmaceutical support, formulation development, laboratory testing, and finished solid dosage and liquid products. Building on a foundation of over seven years of successful consulting, PharmEng in combination with its wholly owned manufacturing subsidiary, Keata, has evolved into one of Canada's leading pharmaceutical companies. PharmEng's shares trade on the TSX Venture Exchange under the symbol PII. For more information about PharmEng, please visit the Company's website at www.pharmeng.com.

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

Contact Information